BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27566026)

  • 1. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
    Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
    Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors.
    Cives M; Anaya DA; Soares H; Coppola D; Strosberg J
    J Natl Cancer Inst; 2018 Mar; 110(3):282-289. PubMed ID: 29741649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.
    Chiramel J; Almond R; Slagter A; Khan A; Wang X; Lim KHJ; Frizziero M; Chakrabarty B; Minicozzi A; Lamarca A; Mansoor W; Hubner RA; Valle JW; McNamara MG
    World J Clin Oncol; 2020 Apr; 11(4):205-216. PubMed ID: 32355642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Factors for Locoregional Recurrence in Neuroendocrine Tumors of the Rectum.
    Tsang ES; McConnell YJ; Schaeffer DF; Yin Y; Speers CH; Kennecke HF
    Dis Colon Rectum; 2018 Feb; 61(2):187-192. PubMed ID: 29337773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and disease recurrence in patients operated for small intestinal neuroendocrine tumors at a referral hospital.
    Folkestad O; Wasmuth HH; Mjønes P; Fougner R; Hauso Ø; Fossmark R
    Surg Oncol; 2020 Dec; 35():336-343. PubMed ID: 32979699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.
    Kim Y; Margonis GA; Prescott JD; Tran TB; Postlewait LM; Maithel SK; Wang TS; Evans DB; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem AI; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Poultsides GA; Pawlik TM
    JAMA Surg; 2016 Apr; 151(4):365-73. PubMed ID: 26676603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.
    Rindi G; Falconi M; Klersy C; Albarello L; Boninsegna L; Buchler MW; Capella C; Caplin M; Couvelard A; Doglioni C; Delle Fave G; Fischer L; Fusai G; de Herder WW; Jann H; Komminoth P; de Krijger RR; La Rosa S; Luong TV; Pape U; Perren A; Ruszniewski P; Scarpa A; Schmitt A; Solcia E; Wiedenmann B
    J Natl Cancer Inst; 2012 May; 104(10):764-77. PubMed ID: 22525418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
    Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
    Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of lymph node metastases, grade and extent of mesenteric lymph node dissection in locoregional small intestinal neuroendocrine tumors with recurrence-free survival.
    Daskalakis K; Wedin M; Tsoli M; Kogut A; Srirajaskanthan R; Sarras K; Kattiparambil S; Giovos G; Weickert MO; Kos-Kudla B; Kaltsas G
    J Neuroendocrinol; 2022 Nov; 34(11):e13205. PubMed ID: 36385444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for the recurrence of sporadic desmoid-type fibromatosis after macroscopically complete resection: Analysis of 114 patients at a single institution.
    He XD; Zhang YB; Wang L; Tian ML; Liu W; Qu Q; Li BL; Hong T; Li NC; Na YQ
    Eur J Surg Oncol; 2015 Aug; 41(8):1013-9. PubMed ID: 26005133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of lymph node metastases and right hemicolectomy on outcomes in appendiceal neuroendocrine tumours (aNETs).
    Alabraba E; Pritchard DM; Griffin R; Diaz-Nieto R; Banks M; Cuthbertson DJ; Fenwick S
    Eur J Surg Oncol; 2021 Jun; 47(6):1332-1338. PubMed ID: 33004273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
    Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
    Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Management of Small Bowel Neuroendocrine Tumors: Specific Requirements and Their Impact on Staging and Prognosis.
    Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
    Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.